Topics:
Neurology • Journal Club ft. NEJM publications • Behavioral Neurology & Neuropsychiatry • Alzheimer
What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?
Are there patients in whom you would specifically avoid this class of treatments?
Answer from: at Academic Institution
All the amyloid antibody trials were conducted in patients without the burden of cerebrovascular disease we often see in clinic populations. Many individuals with cognitive impairment have both vascular and neurogenerative contributions to their decline. We don’t yet know from real-world exper...
Sign in or Register to read more
Answer from: at Community Practice
Lecanemab and donanemab were studied in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. Confirmation with biomarkers and exclusion of other possible causes of dementia is required.
Comments
at Riverside Medical Group
Do you usually check amyloid PET or CSF amyloid? A...
Do you usually check amyloid PET or CSF amyloid? A...